Past & Present
In today’s surgical landscape, existing diagnostic and treatment tools often lack the direct visual context surgeons need to make fast, confident decisions. Without integrated imaging and verification, procedures can become more invasive and complex than necessary, extending recovery times and operational demands. Surgeons also face increasing professional and financial pressures in managing these challenges and ensuring consistent patient outcomes.
The Future
LuminusMicro’s new generation of microsurgical technology is designed to advance precision, safety, and efficiency in surgical care. By integrating real-time visualization with targeted treatment capabilities, our platform aims to reduce the barriers that often accompany traditional procedures.
As healthcare systems worldwide face increasing costs and resource pressures, technologies that streamline care and improve procedural efficiency have never been more essential. The LuminusMicro X1 development program reflects our vision to explore new ways of supporting surgical precision and accessibility across diverse settings.
Footnotes
- Zimlichman E, et al. Health Care–Associated Infections: A Meta-analysis of Costs and Financial Impact on the U.S. Health Care System. JAMA Internal Medicine. 2013;173(22):2039–2046.– Average incremental cost per SSI ≈ $18,600 per patient.
- Anderson DJ, et al. The Impact of Surgical Site Infections on Hospitalization, Costs, and Mortality among Medicare Beneficiaries. Infection Control & Hospital Epidemiology. 2014;35(11):1323–1330.– SSIs associated with an additional 7–10 hospital days (≈ 9 days average).
- Umscheid CA, et al. Estimating the Proportion of Healthcare-Associated Infections that are Reasonably Preventable and the Related Mortality and Costs. Infection Control & Hospital Epidemiology. 2011;32(2):101–114.– Annual U.S. SSI burden estimated at $3.5–10 billion.
- de Lissovoy G, et al. Surgical Site Infection: Incidence and Impact on Hospital Utilization and Treatment Costs. American Journal of Infection Control. 2009;37(5):387–397.– Patients with SSIs incur approximately 1.4 × higher total treatment costs than those without infection.
